when did glp 1 agonists come out GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction GLP-1 for Diabetes vs GLP-1

Description

In Type 2 diabetes, this problem gets worse

doi: 10.1016/S0140-6736(19)31149-3 71 RomeraICebrian-CuencaAAlvarez-GuisasolaFGomez-PeraltaFReviriegoJ

Patients who need weight support today still have safe paths

For example, a methylene-linked oxetane increased potency 100-fold relative to the methyl substituent of 5 , leading to the identification of PF-06882961, which is a full agonist (EC 50 = 13 nM) in the CS cAMP assay (Fig

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population